Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Studie van de invloed van intraperitoneale insufflatie van CO2 door laparoscopie op de kortetermijnevolutie van premature baby's met ulceratieve necrotiserende enterocolitis (NECO2)

4 november 2026 bijgewerkt door: Assistance Publique - Hôpitaux de Paris

Studie van de invloed van intraperitoneale insufflatie van koolstofdioxide (CO2) door laparoscopie op de kortetermijnevolutie van te vroeg geboren baby's met ulceratieve necrotiserende enterocolitis

Ulcerative-necrotizing enterocolitis (ECUN) is an infectious and inflammatory disease of the digestive tract, which can lead to intestinal necrosis or perforation.

This severe pathology of the newborn , often premature, requires urgent medical and surgical treatment in 25 to 50% of cases. The morbidity is high, both digestive and neurological. ECUN can lead to complications at short-term (death, intestinal stenosis) and at long-term (neuro-cognitive disorders). The challenge of preserving the neurological development is a major issue. It involves control of inflammation. This inflammation causes neurological lesions and is responsible for a disorder of the long-term neurocognitive development.

At Robert-Debré and Trousseau, the management of newborns with ECUN is focused on the control of this inflammation. A laparoscopy is performed first. The carbon dioxide (CO2) insufflated into the abdomen during a laparoscopy is thought to have an anti-inflammatory effect according to several experimental and clinical studies. A preliminary retrospective study at Robert-Debré showed a decrease in postoperative inflammation (decrease in C reactive protein at Day2 and Day 7 post-op) as well as a decrease in morbimortality (decrease in the rate of stoma and reoperation) in children who had a laparoscopic first operation compared to those who had a laparotomy alone. However, in many hospitals, laparotomy alone is currently the only surgical option.

This preliminary study may demonstrate that laparoscopy decreases early morbidity and mortality in children with ECUN through reduced inflammation, as reflected by postoperative C reactive protein.

Studie Overzicht

Gedetailleerde beschrijving

NECO2 is a pilot trial, evaluating the intermediate effectiveness to short/medium term of laparoscopy on the inflammatory reaction of premature newborns with complicated ECUN, requiring surgical treatment.

This is a multicenter randomized controlled trial in single blind, in two parallel arms, in ratio 1:1, of superiority.

This trial compares laparoscopy plus laparotomy versus laparotomy alone.

Children will be randomized into 2 groups:

  • Laparoscopy + laparotomy group
  • Laparotomy group

The main objective is to evaluate the inflammatory response Day 2 postoperative in preterm infants with ECUN who have undergone surgery.

The main criterion is the evolution of the blood C reactive protein level between Day 0 and Day 2 postoperatively.

The secondary objectives are:To evaluate in premature babies with ECUN who have had a surgical intervention (laparoscopy + laparotomy or laparotomy alone):

A.The postoperative biological inflammatory response at Day 7 B.Post-operative biological inflammatory response from Day 0 to Day 7 C.Post-operative mortality D.Post-operative bowel morbidity E.Post-operative re-intervention rate F.Length of hospital stay G.Post-operative neurological morbidity, medium term (corrected term 41 SA)

  • To evaluate the tolerance of laparoscopy :

H.Intraoperative cardiorespiratory I.Loco-regional lesions linked to the insertion of the trocar

Secondary endpoints:

A. C reactive protein blood level at Day 7 B. Blood levels of Procalcitonin, Interleukin 6 and Tumor Necrosis Factor-alpha at Day 1, Day 2, Day 4, Day 7 C. Postoperative death from any cause D. Stoma rate, duration of parenteral nutrition, duration of hemodynamic support, duration of invasive ventilation (High frequency oscillatory ventilation/Synchronized Intermittent Mandatory Ventilation), Post-ECUN intestinal stenosis rate E. Re-intervention (laparotomy) and cause (post-ECUN stenosis, stoma closure) F. Length of hospital stay until return home G. Early postoperative neurological lesions observed on transfontanellar ultrasound and MRI at the corrected term of 41 weeks of amenorrhea, H. Oxygen saturation (SaO2), hypercapnia (pCO2) blood pressure (BP), cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) intraoperatively I. Intraoperative clinical monitoring: exploration of adjacent organs. Post-operative clinical monitoring: digestive signs monitoring of wounds until discharge.

Group 1: laparotomy only Group 2: laparotomy and laparoscopy

Studietype

Ingrijpend

Inschrijving (Geschat)

54

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

      • Paris, Frankrijk, 75012
        • Werving
        • Hôpital Armand Trousseau Service de Chirurgie Pédiatrique et Néonatale
        • Contact:
      • Paris, Frankrijk
        • Werving
        • Hôpital Robert Debré Service de Chirurgie Pédiatrique
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Premature newborn (term of birth: <37 weeks of amenorrhea)
  • Diagnosis of ECUN by the surgeon (distension abdominal +/- rectal bleeding +/- green gastric residue, increased biological inflammatory syndrome, + pneumatosis on abdominal radiography)
  • Hospitalized and complicated ECUN: presenting either a pneumoperitoneum on abdominal X-ray or a absence of clinical and biological improvement after 48 hours of maximum well-conducted medical treatment (IV antibiotic therapy and digestive rest).
  • Hospitalized in the 2 participating centers
  • Of which the 2 holders of parental authority have been informed and have signed the consent form
  • Having social security coverage (social security or CMU)

Exclusion Criteria:

  • Instability contraindicating movement to the operating room or contraindicating CO2 insufflation
  • Diagnosis of isolated perforation of the small intestine (radiography:

pneumoperitoneum without pneumatosis)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Laparotomy

Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion

Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion

Experimenteel: Laparotomy and laparoscopy

Exploratory and therapeutic laparotomy if necessary preceded by laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.

Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion

laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
C reactive protein blood level
Tijdsspanne: between Day 0 and Day 2 post surgery

C reactive protein blood level

between Day 0 and Day 2 post surgery

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Postoperative biological inflammatory reaction
Tijdsspanne: Day 7 post surgery

C reactive protein blood level

Day 7 post surgery
Specific post-operative biological inflammatory reaction
Tijdsspanne: Day1, day 2, day 4 and day 7 post surgery

Procalcitonin, Interleukin 6 and Tumor Necrosis Factor-alpha blood level

Day1, day 2, day 4 and day 7 post surgery
Postoperative mortality
Tijdsspanne: up to 3 months

Death due to any postoperative cause

up to 3 months
Postoperative intestinal morbidity: stoma rate
Tijdsspanne: up to 3 months

Stoma rate

up to 3 months
Postoperative intestinal morbidity: Duration of parenteral nutrition
Tijdsspanne: up to 3 months

Duration of parenteral nutrition

up to 3 months
Postoperative intestinal morbidity: Duration of hemodynamic support
Tijdsspanne: up to 3 months

Duration of hemodynamic support

up to 3 months
Postoperative intestinal morbidity: Duration of invasive ventilation (HFO: High frequency oscillatory ventilation/VACI: Synchronized Intermittent Mandatory Ventilation)
Tijdsspanne: up to 3 months

Duration of invasive ventilation (HFO: High frequency oscillatory ventilation/VACI: Synchronized Intermittent Mandatory Ventilation)

up to 3 months
Postoperative intestinal morbidity: Rate of intestinal stenosis post-ECUN
Tijdsspanne: up to 3 months

Rate of intestinal stenosis post-ECUN

up to 3 months
Postoperative reoperation rate
Tijdsspanne: up to 3 months

Reoperation (laparotomy) and cause (post ECUN stenosis, stoma closure)

up to 3 months
Length of hospitalization
Tijdsspanne: up to 3 months

Duration of hospitalization until return home

up to 3 months
Medium-term postoperative neurological morbidity
Tijdsspanne: up to 3 months

Early postoperative neurological lesions observed on transfontanellar ultrasound and MRI at term corrected for 41 weeks of amenorrhea

up to 3 months
Oxygen saturation (SaO2) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Tijdsspanne: During Surgery

Oxygen saturation (SaO2)

During Surgery
Hypercapnia (pCO2) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Tijdsspanne: During Surgery

hypercapnia (pCO2)

During Surgery
Blood pressure (BP) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Tijdsspanne: During Surgery

blood pressure (systolic and diastolic)

During Surgery
Cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Tijdsspanne: During Surgery

cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) intraoperatively

During Surgery
Presence of loco-regional lesions related to the insertion of the trocar (Tolerance of laparoscopy)
Tijdsspanne: up to 3 months

Presence of loco-regional lesions related to the insertion of the trocar

up to 3 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

22 februari 2024

Primaire voltooiing (Werkelijk)

22 juni 2025

Studie voltooiing (Geschat)

22 september 2027

Studieregistratiedata

Eerst ingediend

24 april 2023

Eerst ingediend dat voldeed aan de QC-criteria

26 mei 2023

Eerst geplaatst (Werkelijk)

31 mei 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

6 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren